DRUG · Unmapped registry intervention
D-1553 Tablet
Find medicine records ·
Find other trials using this name
Clinical trial
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
NCT06300177
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Docetaxel injection
Normalized identity: docetaxel InjectionView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedD-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Non Small Cell Lung Cancerunresolved
Interventions
D-1553 TabletDRUG
Docetaxel injectionDRUG · verified · RxNorm: docetaxel Injection
Sponsors & collaborators
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.lead sponsor
Mapped research locations
BeijingBeijing Municipality, China6ChangshaHunan, China5ChongqingChongqing Municipality, China5ZhengzhouHenan, China3FuzhouFujian, China3NanchangJiangxi, China3ShanghaiShanghai Municipality, China2GuangzhouGuangdong, China2HangzhouZhejiang, China2NanjingJiangsu, China2WuhanHubei, China2ShenyangLiaoning, China2
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06300177 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.